Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 7
2018 2
2019 1
2020 3
2021 3
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Fizazi K, et al. Among authors: foulon s. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K. Colomba E, et al. Among authors: foulon s. Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2. Eur Urol. 2024. PMID: 37271630 Clinical Trial.
What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?
Adelon J, Dufour C, Foulon S, Masliah Planchon J, Meyronnet D, Bourdeaut F, Palenzuela G, Fouyssac F, Raimbault S, De Carli E, Klein S, Pagnier A, Bertozzi AI, Rome A, David A, Chabaud S, Faure-Conter C. Adelon J, et al. Among authors: foulon s. J Neurooncol. 2021 Jul;153(3):425-440. doi: 10.1007/s11060-021-03777-9. Epub 2021 Jun 2. J Neurooncol. 2021. PMID: 34076831
Are we reproducible in measurement of NET liver metastasis?
Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E. Moalla S, et al. Among authors: foulon s. Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi: 10.1016/j.dld.2017.05.015. Epub 2017 Jun 28. Dig Liver Dis. 2017. PMID: 28844707
The rising prevalence of chronic myeloid leukemia in France.
Delord M, Foulon S, Cayuela JM, Rousselot P, Bonastre J. Delord M, et al. Among authors: foulon s. Leuk Res. 2018 Jun;69:94-99. doi: 10.1016/j.leukres.2018.04.008. Epub 2018 Apr 17. Leuk Res. 2018. PMID: 29734071
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Frost H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Huddar P, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Rogado J, Romano E, Rowe M, Sekacheva M, Sheehan R, Stevenson J, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Palmieri C, Landers D, Cooksley T; ESMO Co-Care; Dive C, Freitas A, Armstrong AC. Lee RJ, et al. Among authors: foulon s. JCO Clin Cancer Inform. 2022 May;6:e2100177. doi: 10.1200/CCI.21.00177. JCO Clin Cancer Inform. 2022. PMID: 35609228 Free PMC article.
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ, On Behalf Of The Esmo Co-Care. Wysocki O, et al. Among authors: foulon s. Cancers (Basel). 2022 Aug 16;14(16):3931. doi: 10.3390/cancers14163931. Cancers (Basel). 2022. PMID: 36010932 Free PMC article.
25 results